Active-ingredient Dossier
Capecitabine
Active-ingredient Dossier for Capecitabine (antimetabolite chemotherapy agent). Australian brands, products, PBS listings, PBAC outcomes — compiled by…
- Brand: CAPECITABINE
- Brand: CAPECITABINE-DRLA
- Brand: Capecitabine Sandoz
- Brand: XELABINE
- Brand: APO-CAPECITABINE
- Brand: CAPECCORD
- Therapeutic area: Oncology
What is
Capecitabine Capecitabine is an antimetabolite chemotherapy agent.
Australian brands containing
Capecitabine — CAPECITABINE — CAPECITABINE-DRLA — Capecitabine Sandoz — XELABINE — APO-CAPECITABINE — CAPECCORD — XELOCCORD
Therapeutic areas
Capecitabine is registered in oncology, with 7 brands containing the ingredient on the ARTG.
Sponsor landscape
Capecitabine is marketed by five sponsors: Arrotex Pharmaceuticals, Accord Healthcare, Sandoz, Dr Reddys Laboratories, and Viatris.
PBS and regulatory activity
One brand containing capecitabine has PBS-listed items, with the latest PBS schedule date of 1 May 2026. The latest PBAC outcome on record is dated 1 March 2011, with one brand having a PBAC outcome recorded. No AusPARs are on record for capecitabine brands.